Immunotherapy Versus Targeted Therapy for Advanced Melanoma
Adil Daud, MD, compares the roles of immunotherapy versus dabrafenib plus trametinib targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.
Adil Daud, MD, a clinical professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco and director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center, compares the roles of immunotherapy versus dabrafenib (Tafinlar) plus trametinib (Mekinist) targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.
There are pros and cons to either treatment, says Daud. On one hand, patients can receive an oral treatment with a greater incidence of adverse events (AEs) that are more reversible. However, patients also have access to a treatment with a lower incidence of AEs that may be long-lasting and irreversible.
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
